Paper Details

  1. Home
  2. Paper Details

Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).

Author: AthertonPamela J, BartonDebra L, DockterTravis, FlynnKathleen, GillPaula, GriffinPatricia, LafkyJacqueline M, LoprinziCharles L, RanaFauzia N, RieplMike, ShusterLynne T, SloanJeff A, SturtzKeren, TerstriepShelby A, ThielenJacqueline, TsaiMichaela

Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Vaginal dehydroepiandrosterone (DHEA) can improve vaginal symptoms and sexual health in postmenopausal women with estrogen deficiencies. A randomized controlled trial of 464 women found that both 3.25 mg and 6.5 mg DHEA significantly improved vaginal dryness or dyspareunia compared to a plain moisturizer. The 6.5 mg DHEA group also showed significantly better sexual health scores.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Women with estrogen deficiencies can suffer from vaginal symptoms that negatively impact sexual health. This study evaluated vaginal dehydroepiandrosterone (DHEA) for alleviation of vaginal symptoms. METHODS: This three-arm randomized, controlled trial evaluated DHEA 3.25 mg and DHEA 6....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28921241

データ提供：米国国立医学図書館（NLM）

Vaginal Dehydroepiandrosterone for Postmenopausal Cancer Survivors

Vaginal dryness and dyspareunia, common symptoms experienced by postmenopausal women, can significantly impact sexual health. This study evaluates the effectiveness of vaginal dehydroepiandrosterone (DHEA) in alleviating these symptoms in postmenopausal cancer survivors.

The researchers conducted a randomized controlled trial comparing two doses of vaginal DHEA (3.25 mg and 6.5 mg) to a plain moisturizer in postmenopausal women with a history of cancer. They assessed changes in vaginal symptoms and overall sexual health using validated scales.

Their findings suggest that both doses of vaginal DHEA were associated with improvements in vaginal symptoms. The higher dose (6.5 mg) showed a significant improvement in sexual health, suggesting that vaginal DHEA may be a promising treatment option for postmenopausal cancer survivors experiencing vaginal symptoms.

Improving Sexual Health in Cancer Survivors

This study offers hope for postmenopausal cancer survivors experiencing vaginal dryness and dyspareunia. It suggests that vaginal DHEA could be a viable treatment option for improving sexual health and overall quality of life.

Addressing the Needs of Cancer Survivors

This research highlights the importance of addressing the long-term needs of cancer survivors, including those related to sexual health. By exploring treatment options like vaginal DHEA, we can work towards improving the quality of life for these individuals.

Dr.Camel's Conclusion

Just as a camel adapts to its environment, researchers are working to find solutions for the unique needs of postmenopausal cancer survivors. This study suggests that vaginal DHEA may be a valuable tool for improving sexual health and enhancing overall well-being in this population.

Date :
  1. Date Completed 2018-12-18
  2. Date Revised 2019-10-08
Further Info :

Pubmed ID

28921241

DOI: Digital Object Identifier

NIHMS906933

Related Literature

Article Analysis
・Side Effects of prasterone vaginal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.